BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

PartnershipPositive

AI Analysis

Summary

Behavioral Pharma Inc announced a $795M out-licensing deal for its epilepsy program, resulting in an 18% stock price increase. The transaction represents a significant partnership milestone for the company's epilepsy asset.

Outcome Details

$795M out-licensing deal

Importance:7/10

Sentiment:

0.85

out-licensingepilepsypartnershipstock surge

Related Companies

$BHVN

Read the original article

Published by yahoo_finance on August 27, 2026 1:42 PM

Read Original